NephroGenex: Rodman & Renshaw Global Investment Conference (Nephrogenex) - Sep 11, 2014 - "NephroGenex Phase 2 Safety Trials"; "Pyridorin was well tolerated, had a benign safety profile, and slowed the rate of SCr increase in patients on stable SOC at screening"; "There were no meaningful differences between groups in AEs"; "There were increases in diarrhea and consitpation with the higher Pyridorin 300 mg bid dose"; "Diarrhea: Placebo = 6%, 150 mg = 3%, 300 mg = 11%", Constipation: Placebo = 4%, 150 mg = 4%, 300 mg = 10%"; "There were no differences between groups in SAEs, mortality or ESRD"; "There were no differences between groups for laboratory parameters (hematology, chemistry, HbA1c)"; "There was no effect of Pyridorin on the QTc interval"; "Pyridorin has a benign safety profile with the possible exception of a small increase in diarrhea and constipation with the higher dose of 300 mg bid"
P2 data • Diabetic Nephropathy • Renal Disease
|